Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMUEL study
2026-525500-10-00Phase 4Authorised
- Sponsor
- IRBLleida
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of tirzepatide in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity (3 arms), sponsored by IRBLleida. Primary endpoint: Apnea-Hypopnea Index change at week 24. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on 2026-525500-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525500-10-00.